Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,685.99
    -1,652.94 (-3.28%)
     

  • CMC Crypto 200

    1,259.07
    -98.94 (-7.29%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

BUZZ-Smith & Nephew: recovering poise

Reuters - UK Focus

** Artificial joint maker Smith & Nephew (LSE: SN.L - news) bounces off recent lows as Barclays (LSE: BARC.L - news) lifts its rating on the stock to "overweight" vs "equal weight" on valuation grounds and with the bank seeing scope for M&A opportunites.

** S&N up 1.7 pct at 978.62 pence, among top performing stocks on the FTSE 100. Move (NasdaqGS: MOVE - news) closes recent gap lower, and trims losses since June peak to 14 pct.

** Barclays sees two scenarios which could push S&N closer to its blue-sky valuation of 1,500 pence; either S&N deploys $2-3 bln on acquisitions from 2016, which could bring a 10 pct EPS uplift, or S&N is part of a sector consolidation.

** Stock recently hit 6-month lows, suffering along with peers as AbbVie (Xetra: 4AB.DE - news) 's planned Shire inversion deal fell apart.

** Barclays highlights inversion benefits are not the only motivation for strategic healthcare deals. (RM (LSE: RM.L - news) :tricia.wright1.thomsonreuters.com@reuters.net)